Search for immunomodulatory compounds with antiproliferative activity against melanoma

• Published in: Biomedicine & pharmacotherapy Vol. 160; p. 114374
• Main Authors: Jęśkowiak-Kossakowska, Izabela, Jawień, Paulina, Krzyżak, Edward, Mączyński, Marcin, Szafran, Roman, Szeląg, Adam, Janeczek, Maciej, Wiatrak, Benita
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.04.2023; Elsevier
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin - pharmacology; Doxorubicin - therapeutic use; Humans; Immunomodulating Agents; Isoxazole derivatives; Isoxazoles - pharmacology; Melanoma; Melanoma - pathology; Skin cancer; Skin diseases; Skin diseases; Isoxazole derivatives; Melanoma; Skin cancer
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.114374

Melanoma is a highly aggressive neoplasm with a high degree of malignancy and rapid acquisition of resistance by cancer cells. Biological studies of a series of isoxazole compounds with immunomodulatory properties were preceded by in silico analysis. The assay evaluated the viability of NHDF and A375 cell cultures after the administration of isoxazole compounds after a 24-hour incubation period in the MTT test. Analyzes of ROS and NO scavenging, P-glycoprotein activity, and properties were performed. The levels of Caspase 3 and Caspase 9 were measured using ELISA to assess which pathways induced apoptosis by the tested compounds. On the chip, the synergistic effect of doxorubicin and the most active compound from the MM9 series on cells of the A375 melanoma line was determined. All tested N′-substituted derivatives of 5-amino-N,3-dimethyl-1,2-oxazole-4-carbohydrazide with immunomodulatory activity show multidirectional antitumor activity on A375 melanoma lines with an affinity for P-glycoprotein, induction of free radical formation and generation of DNA damage leading to the death of cancer cells, as well as formation of complexes with DNA Topoisomerase II. Most of the tested compounds show pro-apoptotic activity. The most active compound in the series induces apoptosis in three distinct pathways and acts synergistically with doxorubicin. The most active compound with immunomodulatory properties showed multidirectional antitumor activity against cells of the A375 melanoma line and also had a synergistic pro-apoptotic effect with doxorubicin, which may result in a reduction of this cytostatic dose with increased effectiveness. [Display omitted] •The isoxazole derivatives MM have multidirectional antitumor activity against A375 melanoma cell line and synergistic effect with doxorubicin.